液態檢體檢測於醫療生技產業商業模式探討

Abstract

醫療體制的均衡發展為長期存在的問題，政府、醫院、製藥公司、醫學檢驗、保險、生技公司、資本、病患、倫理等，存在如何維持平衡的取捨難題，提出新的商業模式來做為解決方案成為各方努力之機會所在。探討在不同視野下醫療生技產業衡量跨界資源與產業生態平衡的思路。期望在國家制定產業政策時有更前瞻的思維，進而有效提升國際化實質競爭能力、建立醫療生技企業更全面的綜合發展策略，資本市場在醫療生技產業的運作更加全面宏觀上做出貢獻。

The balanced development of the medical system is a long-standing issue. Specially, challenges have occurred in maintaining a balance among factors such as the government, hospitals, pharmaceutical companies, medical laboratories, insurance companies, biotechnology, capital, patients, and ethics. Therefore, a new business model might be of interest to relevant parties who wish to resolve such challenges. This study, from various perspectives, discussed the medicine and biotechnology industry’s mindset in gaining interdisciplinary resources and obtaining a balance in the industrial ecosystem. The study’s findings may contribute to building a pioneering mindset of the country in industrial policy formulation, which could effectively improve its international competitiveness; to establishing comprehensive developmental strategies in medical and biotechnological companies; and to realizing the medicine and biotechnology industry’s comprehensive operations at the macro level in capital markets. Keyword：Medicine and Biotechnology Management、Liquid Biopsy、In Vitro Diagnostic Device(IVD)、Precision Medicine、Theranos